Vestal Point Capital LP Boosts Stock Position in Lexeo Therapeutics, Inc. (NASDAQ:LXEO)

Vestal Point Capital LP increased its holdings in Lexeo Therapeutics, Inc. (NASDAQ:LXEO - Free Report) by 41.2% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 1,200,000 shares of the company's stock after purchasing an additional 350,000 shares during the quarter. Vestal Point Capital LP owned 3.63% of Lexeo Therapeutics worth $7,896,000 at the end of the most recent reporting period.

A number of other large investors also recently bought and sold shares of the business. Bank of New York Mellon Corp raised its holdings in Lexeo Therapeutics by 5.6% in the 4th quarter. Bank of New York Mellon Corp now owns 50,660 shares of the company's stock worth $333,000 after purchasing an additional 2,677 shares during the period. JPMorgan Chase & Co. raised its holdings in Lexeo Therapeutics by 30.1% in the 4th quarter. JPMorgan Chase & Co. now owns 13,371 shares of the company's stock worth $88,000 after purchasing an additional 3,093 shares during the period. Wells Fargo & Company MN raised its holdings in Lexeo Therapeutics by 49.9% in the 4th quarter. Wells Fargo & Company MN now owns 11,156 shares of the company's stock worth $73,000 after purchasing an additional 3,714 shares during the period. Rhumbline Advisers raised its holdings in Lexeo Therapeutics by 19.6% in the 4th quarter. Rhumbline Advisers now owns 25,197 shares of the company's stock worth $166,000 after purchasing an additional 4,127 shares during the period. Finally, Barclays PLC raised its holdings in Lexeo Therapeutics by 9.9% in the 4th quarter. Barclays PLC now owns 55,161 shares of the company's stock worth $363,000 after purchasing an additional 4,951 shares during the period. Institutional investors and hedge funds own 60.67% of the company's stock.

Lexeo Therapeutics Price Performance

Shares of Lexeo Therapeutics stock traded down $0.26 during mid-day trading on Friday, reaching $2.82. 480,722 shares of the stock traded hands, compared to its average volume of 489,318. The business has a 50-day moving average of $3.09 and a 200 day moving average of $4.80. Lexeo Therapeutics, Inc. has a fifty-two week low of $1.45 and a fifty-two week high of $19.50. The stock has a market capitalization of $93.62 million, a PE ratio of -0.89 and a beta of 1.27. The company has a quick ratio of 5.95, a current ratio of 5.95 and a debt-to-equity ratio of 0.01.

Lexeo Therapeutics (NASDAQ:LXEO - Get Free Report) last posted its quarterly earnings results on Monday, May 12th. The company reported ($0.99) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.80) by ($0.19). On average, analysts predict that Lexeo Therapeutics, Inc. will post -3.14 EPS for the current year.

Analyst Ratings Changes

A number of equities analysts recently weighed in on LXEO shares. HC Wainwright reduced their price target on Lexeo Therapeutics from $23.00 to $15.00 and set a "buy" rating for the company in a report on Friday, May 16th. Royal Bank of Canada reduced their target price on Lexeo Therapeutics from $24.00 to $20.00 and set an "outperform" rating for the company in a report on Tuesday, March 25th. Chardan Capital reduced their target price on Lexeo Therapeutics from $22.00 to $20.00 and set a "buy" rating for the company in a report on Tuesday, May 13th. Finally, Leerink Partners reduced their target price on Lexeo Therapeutics from $19.00 to $18.00 and set an "outperform" rating for the company in a report on Monday, March 24th. Five equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the company has an average rating of "Buy" and an average target price of $20.20.

Lexeo Therapeutics Company Profile

Lexeo Therapeutics, Inc operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene.